Agendia's MammaPrint shows significant agreement with other multi-gene breast cancer prognosis tests
Dr. Charles Perou, senior author of the New England Journal of Medicine states in the publication that it is clear that these profiles provided significant additional information beyond that provided by grade (i.e. histological assessment of tumor aggressiveness). In a commentary in the same issue of the New England Journal of Medicine, Dr. Joyce O'Shaughnessy comments that multi-gene tests will alter medical practice such that in the future 30- to 50% fewer patients with ER-positive breast cancer will receive adjuvant chemotherapy.
Most read news
Other news from the department business & finance
Get the analytics and lab tech industry in your inbox
From now on, don't miss a thing: Our newsletter for analytics and lab technology brings you up to date every Tuesday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.